Latest by Tracy Swan, presented at HEP DART 2009

Hepatitis C Virus (HCV) and HIV/HCV Coinfection: A Critical Review of Research and Treatment

Table of Contents

Credits Acknowledgements Dedication Foreword

Volume I: Clinical Science

Executive Summary Introduction I. Epidemiology of Hepatitis C II. Natural History of Hepatitis C III. Natural History of HCV in HIV Coinf...

By Tracy Swan, presented at HEP DART 2009 and Bob Huff for Treatment Action Group

The "G" Word: Gilead's Greed Gives Rise to a Slew of Advocacy Priorities

Activists are decrying Gilead's refusal to continue codeveloping a winning HCV drug combination with Bristol-Myers Squibb (BMS), opting instead to focus on co-formulations of its own promising agents. While a high-level petition continues to circulat...

By Tracy Swan, presented at HEP DART 2009 for Treatment Action Group

Cure Rates With Pipeline HCV Drugs: Reports From AASLD

It is difficult to be anything other than dazzled by astounding cure rates of up to 100% from a multitude of interferon-free hepatitis C virus (HCV) clinical trials presented at the American Association for the Study of Liver Diseases (AASLD) meeting...

By Tracy Swan, presented at HEP DART 2009 for HIV i-Base

What You Don't Know, You Can Sell

Many people with HIV also have hepatitis C. So why did it take so long to see information about potentially serious interactions between HIV drugs and Victrelis (boceprevir), a new hep C medication? Activist Tracy Swan offers this sharp critique.

By Tracy Swan, presented at HEP DART 2009 for Treatment Action Group

The Hepatitis C Treatment Pipeline

Table of Contents

The Thrill Is Already Gone Evolution to Revolutionary? Clinical Issues in the United States Access Issues Diagnostics Research Issues Plea for Simplicity Most Need, Least Data Drug-Drug Interactions Current Resear...

By Tracy Swan, presented at HEP DART 2009 for Treatment Action Group

Guide to Clinical Trials for People With Hepatitis C

There are many new hepatitis C drugs being studied in clinical trials. People with hepatitis C have many options to choose from. Whether you have hepatitis C or another medical condition, deciding to participate in a clinical trial can be complicated...

By Tracy Swan, presented at HEP DART 2009 and Matt Sharp for Treatment Action Group

Access to Hepatitis C Treatment: A Global Movement Gains Momentum

Being a person living with HIV/AIDS, hepatitis C, and an injection drug user, I look at my body. People want to treat my virus -- my immune system -- people want to treat my chest -- my TB -- but no one wants to treat my liver, so we have to find som...

By Tracy Swan, presented at HEP DART 2009 for Treatment Action Group

Terms For Response to HCV Treatment

Treatment Response: Response to hepatitis C treatment is measured by change in HCV viral load at different time points. Since it is a common practice to release interim data from HCV treatment trials, it is important to understand what these terms me...

By Tracy Swan, presented at HEP DART 2009 for Treatment Action Group

Rapidly Progressing Hepatitis C in New York Gay Men

Recent outbreaks of acute hepatitis C virus (HCV) among HIV-positive men who have sex with men (MSM) have been reported in England, France, Germany, Holland, and the United States. Many of these cases were sexually transmitted, which is unusual becau...

By Tracy Swan, presented at HEP DART 2009 for Treatment Action Group

Other Viral Hepatitis Infections

Other Viral Hepatitis Infections

Hepatitis A (HAV)

HAV is found in feces (stool). People become infected when feces from a person who is infected with HAV enters their mouth. This may occur when food (including raw or undercooked shellfish) or wate...

By Simon Collins and Tracy Swan, presented at HEP DART 2009 for Treatment Action Group